Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
István Laáng
Institution:
National Institute of Oncology
Observed institution:
National Institute of Oncology
ORCID:
0009-0007-1224-6322
Observed ORCID:
0009-0007-1224-6322
OpenAlex ID:
A5113060361
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
·
Clinical Cancer Research
·
13
PDF
Data from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S3 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Table S9 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Table S5 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S8 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S13 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Table S6 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Table S8 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Table S2 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Table S7 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Figure S12 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Figure S11 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S7 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S9 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S5 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S14 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S15 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S6 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Table S4 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Table S3 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S2 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Supplementary Figure S4 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Figure S1 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
PDF
Supplementary Figure S16 from Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
2023
·
Andrea Joaquin Garcia
, Mattia Rediti
, et al.
Show more works
View as search
Works count:
28
Citation count:
13
H-index:
1
I10-index:
1
Year
Topic
Type